Will Oruka Therapeutics stock go up?

According to Danelfin AI, Oruka Therapeutics has today an AI Score of 7/10 (Buy rating), because its probability of beating the market in 3 months (59.62%) is +8.80% vs. the average probability (50.82%) of all US-listed stocks.

What is the target price for Oruka Therapeutics stock?

The Oruka Therapeutics target price is $85.23 (1Y), according to the average price target offered by analysts.

Is it a good time to buy, sell, or hold Oruka Therapeutics stock right now?

Oruka Therapeutics has today a Buy rating (AI Score 7/10), according to Danelfin AI. Its probability of beating the market in 3 months (59.62%) is +8.80% vs. the average probability (50.82%) of all US-listed stocks, based on our AI-powered analysis. You can find more details on whether Oruka Therapeutics stock is a good buy .

Is Oruka Therapeutics undervalued right now?

Based on analysts, the average price target downside for Oruka Therapeutics is 0.00% (1Y). According to Danelfin AI, Oruka Therapeutics has today an AI Score of 7/10 (Buy Rating).

What was the price range of Oruka Therapeutics stock over the past 12 months?

The Oruka Therapeutics stock price range over the past 12 months has been $10.9 - $95.17.

What is going on with Oruka Therapeutics stock in the last 3 months?

The Oruka Therapeutics stock performance in the last quarter has been +69.00%.

Does Oruka Therapeutics offer dividend payments?

No, Oruka Therapeutics does not currently pay dividends.

What is the current market capitalization of Oruka Therapeutics?

Oruka Therapeutics's market cap is $5.14B, as of 2026-07-03 08:00.

Oruka Therapeutics Inc (ORKA) AI Stock Analysis

Advanced Chart

Custom range

Jul 3, 2025

→

Jul 3, 2026

Custom range

Jul 3, 2025

→

Jul 3, 2026

ORKA AI-Powered Stock Analysis

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

Momentum+3.62%
Direction and strength of recent price movements
Valuation+3.00%
How the stock is priced relative to its fundamentals
Earnings Quality+0.92%
Stability and reliability of reported earnings
Sentiment+0.78%
How analysts and the market view the stock
Growth+0.42%
Expected pace of revenue and earnings expansion
Size & Liquidity+0.25%
Company size and trading liquidity

Volatility-0.19%
How much the stock price tends to fluctuate

ORKA probability advantage of beating the market (3M):

+8.80%

AI Score

Buy

Oruka Therapeutics (ORKA) has an AI Score of 7/10 (Buy) because, according to an overall analysis, it has a probability advantage of +8.80% of beating the market (S&P500) in the next 3 months. This advantage is calculated as the difference between the average probability of any US-listed stock (50.82%) and the probability of ORKA (59.62%) of outperforming the market in the next 3 months, as determined by Danelfin AI’s comprehensive analysis.

Average probability of any US-listed stock of beating the market (3M)50.82%
ORKA probability advantage of beating the market (3M)+8.80%
ORKA probability of beating the market (3M)59.62%

ORKA probability advantage of beating the market (3M): +8.80%

The AI-powered overall analysis of Oruka Therapeutics (ORKA) is based on the 27 fundamental, technical, and sentiment features that had the greatest impact on stock performance during the last 12 months (alpha signals). These alpha signals explain the probability advantage of ORKA:

Type	Alpha Signal	Current Value	Value Decile Position	Probability Advantage Impact (3M)
Fundamental	Fundamentals Impact (Long Tail)	-	N/A	+2.61%
Technical	Chart Pattern (504d)	figure_21	N/A	+1.15%
Fundamental	Operating Cash Flow (Qtr Discrete)	-23.58		+0.92%
Sentiment	Industry (GICS)	Biotechnology	N/A	+0.66%
Technical	Technicals Impact (Long Tail)	-	N/A	+0.61%
Technical	Chart Pattern (120d)	figure_83	N/A	+0.59%
Sentiment	Fear & Greed Index (CNN)	31	N/A	-0.56%
Fundamental	Cash per Share (MRQ)	6.45		+0.56%
Technical	Alpha Last Day	-0.09%	N/A	+0.53%
Technical	Chart Pattern (90d)	figure_11	N/A	+0.50%
Sentiment	Upgrade to unlock			+0.44%
Sentiment	Upgrade to unlock			+0.42%
Fundamental	Upgrade to unlock			-0.36%
Technical	Upgrade to unlock			+0.34%
Sentiment	Upgrade to unlock			-0.31%

Rest of Alpha Signals: +0.70%

ORKA probability advantage of beating the market (3M)Total:+8.80%
ORKA AI Score

Significant changes Vs previous day

ORKA Trading Parameters

These suggested trading parameters for a 3-month horizon help improve risk management and decision-making.

Entry:$85.23
Horizon: 3 months
Stop Loss:$XXXXXPro (XXXXXPro) or AI Score < 7/10
Take Profit:$XXXXXPro (XXXXX
Pro
) or AI Score < 7/10

ORKA Proven Buy Signal & Price Forecast

This is the price chart for ORKA from January 2, 2026 until today. The chart indicates, in green, the 19 days when the stock received a Buy/Strong Buy rating (buy signals, AI Score 7 to 10).

Forecast: In the section below, the central dotted line represents the most expected path, while the shaded area indicates the anticipated price range. This is based on previous Buy signals with a 90% confidence level.

Full Track Record

Unlock AI-powered forecast

Closing price (USD)
Buy signals

Forecast:

1 Month
3 Months
6 Months
1 Year

ORKA Average Past Performance & Win Rate

Three months after its 107 Buy signals since July 2026, ORKA had an average performance of xxxxxxx and a xxxxxx Win rate (positive performance).

107 Past ORKA Buy Signals	1 Month Later	3 Months Later	6 Months Later	1 Year Later
Average Performance				-15.15%
Average Alpha				-18.79%
Win Rate (% Positive Perf.)				10.47%
% Positive Alpha				11.63%

ORKA Frequently Asked Questions

Will Oruka Therapeutics stock go up?
According to Danelfin AI, Oruka Therapeutics has today an AI Score of 7/10 (Buy rating), because its probability of beating the market in 3 months (59.62%) is +8.80% vs. the average probability (50.82%) of all US-listed stocks.
What is the target price for Oruka Therapeutics stock?
Is it a good time to buy, sell, or hold Oruka Therapeutics stock right now?
Is Oruka Therapeutics undervalued right now?
What was the price range of Oruka Therapeutics stock over the past 12 months?
What is going on with Oruka Therapeutics stock in the last 3 months?
Does Oruka Therapeutics offer dividend payments?
What is the current market capitalization of Oruka Therapeutics?

Oruka Therapeutics Inc Company Profile

Oruka Therapeutics Inc (ORKA) is a biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapeutic candidates. It focuses on addressing serious diseases characterized by significant unmet medical needs. The company's mission involves advancing innovative medicines to improve patient outcomes. It primarily serves patients and healthcare providers who seek advanced and effective treatment options across various therapeutic areas.

The company's core research and development efforts are concentrated within the field of immunology. It develops precision medicines specifically designed to modulate complex immune responses. These therapeutic programs aim to treat a range of autoimmune disorders, chronic inflammatory conditions, and other immune-mediated diseases. Oruka Therapeutics leverages advanced biological platforms and proprietary technologies to identify and optimize its drug candidates. Its pipeline includes multiple investigational therapies, each targeting specific immune pathways and mechanisms of action. This approach seeks to offer more targeted and potentially safer treatment alternatives.

Oruka Therapeutics also pursues robust therapeutic programs in oncology, developing innovative treatments for various types of cancer. These therapies often involve targeted approaches, such as small molecules or biologics, designed to interfere with cancer growth and progression. The company's scientific teams work diligently to advance these candidates through preclinical and clinical development stages. Furthermore, Oruka Therapeutics maintains a dedicated focus on rare diseases, where it endeavors to provide critical solutions for underserved patient populations. Its efforts in this domain aim to address conditions with limited or no existing treatment options, emphasizing patient quality of life.

Oruka Therapeutics serves a global patient population through collaborations with healthcare professionals, hospitals, and specialized treatment centers. Its distribution strategy involves establishing a direct sales presence in key strategic markets to engage directly with prescribers. The company also collaborates with a network of strategic partners and distributors to ensure broader market access and reach across different geographies. Revenue is generated primarily from the sale of its commercialized pharmaceutical products. It also includes potential milestone payments and royalties derived from strategic collaborations and licensing agreements for its intellectual property. The company generates revenue through product sales and potential licensing agreements, distributed through a combination of direct sales and channel partners, reaching a global market.

Sector:
Country:United States
Industry:
Address:855 Oak Grove Ave., Suite 100, Menlo Park
Employees:68
Website:orukatx.com

Pros

Proprietary intellectual property protection for novel therapies

High patient switching costs for established treatments

Potential for premium pricing in specialized therapeutic areas

Scalability of manufacturing and distribution post-approval

Addressing unmet medical needs in specific disease indications

Cons

Extensive capital requirements for research and development

High regulatory approval risk for drug candidates

Exposure to patent expiration and generic competition

Clinical trial failure rates for pipeline assets

Reimbursement pressure from healthcare payers

Company	AI Score	Compare
ZURAZura Bio Ltd

Company	AI Score	Compare
ZURAZura Bio Ltd

ORKA Stock AI Analysis